



# Manhattan Scientifics Files Form 8-K Describing Recent Milestone Payment

November 1, 2010

NEW YORK--Manhattan Scientifics Inc. (OTCBB: MHTX), a nanomedicine technology transfer and commercialization pioneer, announced today that it has filed a Current Report on [Form 8-K](#) with the Securities Exchange Commission describing the terms of the company's recent milestone payment.

Manhattan Scientifics received a \$1 million milestone payment from Carpenter Technologies, Inc. (CRS), the company's collaborative partner on nanometals technology for satisfying its performance obligations under the Technology Transfer Agreement between the parties dated August 12, 2009.

At a recent press conference the company also announced the official start of its production and sales of nanostructured titanium dental implants. The press conference is now available for viewing at the company's website and at the following link, <http://www.mhtx.com/press-conference.htm>.

## About Manhattan Scientifics

Manhattan Scientifics, Inc., (OTCBB: MHTX), is a leading information age enterprise focused on the nanomedicine space. Located in New Mexico, New York and Montreal, Manhattan Scientifics' goal is to create profit for the company's shareholders through royalty-bearing licenses with Fortune 1000 companies by marketing products that rely on the company's patents, know-how and intellectual property. Manhattan Scientifics owns the exclusive, perpetual U.S. license to a family of patents which will enable the manufacture and marketing of super strong, ultra light-weight "nanostructured" metals that have been developed at the Los Alamos National Laboratory (LANL) and in the former Soviet Union. More information about Manhattan Scientifics can be found at [www.mhtx.com](http://www.mhtx.com) and at [www.seniorscientific.com](http://www.seniorscientific.com)

## Forward-looking statement

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

## Contacts

### Manhattan Scientifics, Inc.

Marvin Maslow, Director of PR & IR, 917-923-3300

Email: [marvin@mhtx.com](mailto:marvin@mhtx.com)

---



**U.S. & Canadian Investor Relations**

Hawk Associates: Frank Hawkins, 305-451-1888

Email: [f.hawkins@hawkassociates.com](mailto:f.hawkins@hawkassociates.com)